Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
about
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationLymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processesStable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignanciesReduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesT-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemiaEBV-associated lymphomas in adultsAnti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.Viral infections and their management in patients with chronic lymphocytic leukemia.Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.The targeting of immunosuppressive mechanisms in hematological malignancies.Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.Association of Epstein-Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation.Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.Large-scale multiplex polymerase chain reaction assay for diagnosis of viral reactivations after allogeneic hematopoietic stem cell transplantation.Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival.Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC
P2860
Q28072627-4FB6D623-AC57-4F69-B614-8D0220D838E0Q28271456-E568FA7A-EB51-4E8A-ADE8-E5361797D724Q33576014-9F5E5BE7-150B-4157-A18C-C2787158BB6AQ33795160-BEF53ED6-7002-4169-9030-14DDC98CA5DEQ34463645-C6AE46EA-2CAA-4191-9AED-9AC786E11CC2Q34557915-162E0583-F4FF-448C-BCA9-83BA527039A3Q34636601-C3BE216A-6A33-4ABE-A70E-F23211103411Q37016397-E3DA72DA-EC43-416A-9BBC-F988BDFBE60AQ37426542-B9DE1011-E66B-46EE-A80D-91FBBB24F64BQ37552052-BA420F53-6993-403F-9502-F397EA198261Q38064527-ED53B5A2-7F57-48B7-A9D3-710CC9586F67Q38098957-AFE2D50E-8BF5-4D4B-A8DE-55D3D4E2A505Q38201231-FE408A90-2B51-40FF-81A9-1C763EBC8BCCQ38226100-AA388920-8BC1-4642-899D-D1897D5C65CDQ40474718-6513BA64-3916-492B-86B4-D3EF69D922B5Q40518920-8C9360C2-EBB1-4CF8-A4C6-6288BC59AE6CQ40907778-334BACC1-3AA0-4D1F-9BC9-137ACE1984BAQ41758098-3469684E-85EA-4C79-BECF-62EBA456E366Q42244554-23712D68-ACCA-4BCB-9821-FDF2807F0552Q45350676-F4BFA12B-72ED-4EC7-8946-9852BFE8D0C7Q45352633-7AF5013E-2A55-4563-814A-B4F0A1784891Q54379261-2604E55C-2743-43D4-942F-343C27BCCCAFQ57808500-3EA34F28-79B8-46F8-BF9D-614D08488883
P2860
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Features of Epstein-Barr Virus ...... tic stem cell transplantation.
@en
Features of Epstein-Barr Virus
@nl
type
label
Features of Epstein-Barr Virus ...... tic stem cell transplantation.
@en
Features of Epstein-Barr Virus
@nl
prefLabel
Features of Epstein-Barr Virus ...... tic stem cell transplantation.
@en
Features of Epstein-Barr Virus
@nl
P2093
P2860
P356
P1433
P1476
Features of Epstein-Barr Virus ...... etic stem cell transplantation
@en
P2093
B Saulquin
B-M Imbert-Marcille
J Delaunay
J-L Harousseau
M Coste-Burel
P2860
P2888
P304
P356
10.1038/LEU.2011.26
P577
2011-02-25T00:00:00Z
P5875
P6179
1005543088